<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Eur Cardiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur Cardiol</journal-id>
<journal-id journal-id-type="publisher-id">ECR</journal-id>
<journal-title-group>
<journal-title>European Cardiology Review</journal-title>
</journal-title-group>
<issn pub-type="ppub">1758-3756</issn>
<issn pub-type="epub">1758-3764</issn>
<publisher>
<publisher-name>Radcliffe Cardiology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32180835</article-id>
<article-id pub-id-type="pmc">7066852</article-id>
<article-id pub-id-type="doi">10.15420/ecr.2019.03</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nakao</surname>
<given-names>Shu</given-names>
</name>
<xref ref-type="aff" rid="aut1">1</xref>
<xref ref-type="aff" rid="aut2">,2</xref>
<xref ref-type="aff" rid="aut3">,3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ihara</surname>
<given-names>Dai</given-names>
</name>
<xref ref-type="aff" rid="aut1">1</xref>
<xref ref-type="aff" rid="aut2">,2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hasegawa</surname>
<given-names>Koji</given-names>
</name>
<xref ref-type="aff" rid="aut3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kawamura</surname>
<given-names>Teruhisa</given-names>
</name>
<xref ref-type="aff" rid="aut1">1</xref>
<xref ref-type="aff" rid="aut2">,2</xref>
<xref ref-type="aff" rid="aut3">,3</xref>
</contrib>
<aff id="aut1"><label>1.</label>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan</institution></aff>
<aff id="aut2"><label>2.</label>
<institution>Global Innovation Research Organization, Ritsumeikan University, Kusatsu, Japan</institution></aff>
<aff id="aut3"><label>3.</label>
<institution>Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan</institution></aff>
</contrib-group>
<author-notes>
<fn fn-type="COI-statement">
<p><bold>Disclosure</bold>: This work was supported by grants from JSPS KAKENHI (to TK and SN) and an Inamori Foundation Research Grant for Natural Sciences (to SN). TK is the group leader of the research project supported by Ritsumeikan Global Innovation Research Organization (R-GIRO). All other authors have no conflicts of interest to declare.</p>
</fn>
<corresp id="cor1"><bold>Correspondence</bold>: Teruhisa Kawamura, 1–1-1 Noji-higashi, Kusatsu, Shiga 525-8577, Japan. E: <email>kawater@fc.ritsumei.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>15</volume>
<elocation-id>e02</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020, Radcliffe Cardiology</copyright-statement>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">
<license-p>This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.</license-p>
</license>
</permissions>
<abstract>
<p>Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (h)iPSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.</p>
</abstract>
<kwd-group>
<kwd>Induced pluripotent stem cell</kwd>
<kwd>cardiomyocyte</kwd>
<kwd>genetic disease</kwd>
<kwd>drug screening</kwd>
<kwd>gene editing</kwd>
</kwd-group>
<counts>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Induced Pluripotent Stem Cells and Their Potential Applications</title>
<p>Induced pluripotent stem cells (iPSCs) are generated from somatic cells, such as skin fibroblasts, by ectopic expression of defined reprogramming factors. Within a few years of the first report of the generation of mouse iPSCs, several laboratories reportedly reproduced these cells using other cell types and species using similar approaches.[<sup><xref ref-type="bibr" rid="r1">1</xref>–<xref ref-type="bibr" rid="r4">4</xref></sup>] This early attention on reproducible methods for the production of iPSCs from mammalian cells accelerated research into iPSC technology for clinical applications. iPSCs show unlimited proliferation capacity and pluripotency, as observed in embryonic stem cells (ESCs), and thus have significant advantages as a cell source for producing sufficient numbers of any cell type. In contrast with ESCs, human (h) iPSCs can be established from differentiated cells without destroying human embryos, thereby overcoming related ethical issues. Thus, iPSCs have been extensively investigated worldwide for applications in disease modelling, drug screening and regenerative medicine (<italic><xref ref-type="fig" rid="fig1">Figure 1</xref></italic>).[<sup><xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r5">5</xref></sup>]</p>
<p>When hiPSCs are derived from patients with a genetic disease caused by a mutation, such patient-derived iPSCs are called disease-specific hiPSCs. As disease-specific hiPSCs contain the same genetic information as the patient, including mutations corresponding to the altered gene function,[<sup><xref ref-type="bibr" rid="r6">6</xref>,<xref ref-type="bibr" rid="r7">7</xref></sup>] disease-specific hiPSCs could potentially be a powerful tool for modelling human disease. Particularly in cardiovascular research, obtaining a sufficient number of cardiomyocytes (CMs) from patients is challenging due to the highly invasive procedures required to extract them. Further, the low proliferation capacity of CMs limits researchers’ ability to maintain these cells in culture. Being able to generate iPSC-derived CMs (hiPSC-CMs) from a specific patient overcomes this problem, and enables identification of typical cellular responses to pathological stress and therapeutic agents because these cells potentially reflect the biological responses of an individual patient’s own CMs (<italic><xref ref-type="fig" rid="fig1">Figure 1</xref></italic>).</p>
<p>Recent genetic research has led to the identification of gene mutations responsible for hereditary heart diseases. Investigations into the pathophysiology of those inherited diseases often use animal models that partially mirror the disease conditions. However, animal studies are low throughput, time consuming and relatively expensive. Moreover, there are interspecies differences between humans and the experimental animals in terms of molecular and physiological properties (e.g. ion channel expression profile, heart rate), as well as in the cellular responses to pathological stress. Therefore, experimental results obtained from animal models do not perfectly recapitulate the conditions occurring in humans, and are less reliable for the purpose of extrapolation. In contrast, disease-specific hiPSCs could be a valuable tool in research on inherited diseases and for testing therapeutic agents. hiPSCs are created from somatic cells, which can be easily collected from accessible patient tissues, such as skin and blood. Owing to their self-renewal property, hiPSCs could be used to produce a sufficient number of specific cell types following appropriate differentiation methods for further experiments <italic>in vitro</italic>.</p>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1:</label>
<caption>
<title>Human Induced Pluripotent Stem Cell Applications in Cardiovascular Medicine</title>
</caption>
<graphic xlink:href="ecr-15-2-g001"></graphic>
<p>Cas9 = CRISPR-associated 9; CRISPR = clustered regularly interspaced short palindromic repeat; iPSC = induced pluripotent stem cell.</p>
</fig>
</sec>
<sec>
<title>Human Induced Pluripotent Stem Cells for Modelling Inherited Arrhythmias</title>
<p>Advances in cardiovascular research have increased our understanding of the molecular mechanisms underlying various genetic diseases. Comprehensive genetic studies have identified causal mutations responsible for phenotypes of inherited cardiovascular diseases such as long QT syndrome (LQTS), Brugada syndrome and cardiomyopathies.</p>
<p>LQTS is characterised by a significantly prolonged QT interval attributable to delayed repolarisation in the ventricular myocardium. Some types of LQTS cause life-threatening arrhythmias in response to stimuli such as swimming and sudden loud noise. Genetic studies have found a number of gene loci responsible for LQTS in families with a high incidence of the disease. Despite an absence of clinical symptoms under sedentary conditions in patients with LQTS, once ventricular tachyarrhythmias are triggered by specific stimuli, patients with LQTS are prone to exhibit syncope. Sustained arrhythmias ultimately lead to VF, resulting in sudden cardiac death. Several studies on patients with LQTS have identified a number of mutations in genes encoding cardiac ion channels, which are membrane proteins regulating the generation and propagation of action potential.[<sup><xref ref-type="bibr" rid="r8">8</xref>–<xref ref-type="bibr" rid="r10">10</xref></sup>] However, these mutations are not always responsible for the observed symptoms, even when the patients are exposed to the stimuli that trigger electrophysiological changes.</p>
<p>Effects of the stimuli or therapeutic agents, as well as the incidence of cardiac events, vary considerably among individual patients. Therefore, to address issues related to proarrhythmic mechanisms in individuals with inherited LQTS, patient-derived hiPSC-CMs with the corresponding mutation(s) could serve as powerful tools for <italic>in vitro</italic> experiments. Previous studies characterising mutations of the alpha-subunit of the potassium voltage-gated channel subfamily Q member 1 (<italic>KCNQ1</italic>; also known as K<sub>V</sub>LQT1 and K<sub>V</sub>7.1) using patient-derived iPSC-CMs revealed that impaired membrane trafficking of Ks channels and reduced delayed rectifier potassium channel current (<italic>I</italic><sub>Kr</sub>) cause LQT1.[<sup><xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r11">11</xref>,<xref ref-type="bibr" rid="r12">12</xref></sup>] Itzhaki et al. introduced reprogramming factors into dermal fibroblasts obtained from patients with a mutation in the alpha-subunit of potassium voltage-gated channel subfamily H member 2 (<italic>KCNH2</italic>; responsible for <italic>I</italic><sub>Kr</sub>) causing LQT2.[<sup><xref ref-type="bibr" rid="r13">13</xref></sup>] Spontaneously beating hiPSC-CMs carrying this mutation were used for functional analysis and exhibited a prolonged QT interval similar to that in LQTS patients.</p>
<p>Similar studies using hiPSC-CMs derived from a patient with a missense mutation in <italic>KCNH2</italic> also exhibited action potential prolongation, smaller <italic>I</italic><sub>Kr</sub>, early afterdepolarisations and arrhythmias. These changes were recovered or exaggerated by pharmacological agents or selective RNA interference in disease-specific hiPSC-CMs.[<sup><xref ref-type="bibr" rid="r13">13</xref>–<xref ref-type="bibr" rid="r16">16</xref></sup>]</p>
<p>Disease-specific hiPSC-CMs from patients and families with Timothy syndrome (LQT8) that have a mutation located in calcium voltage-gated channel subunit alpha1 C (<italic>CACNA1C</italic>; responsible for the L-type calcium current, <italic>I</italic><sub>Ca,L</sub>) have been established and assessed for mutation-associated phenotypes <italic>in vitro</italic>.[<sup><xref ref-type="bibr" rid="r10">10</xref>,<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r18">18</xref></sup>] An LQT8 model using patient-specific hiPSC-CMs reflected cellular electrical abnormalities, including prolonged action potential duration, delayed afterdepolarisations and altered Ca<sup>2+</sup> transients. In contrast, roscovitine, an inhibitor of cyclin-dependent kinase 5, a key mediator involved in the regulation of Ca<sub>V</sub>1.2 channels, enhanced <italic>I</italic><sub>Ca,L</sub> inactivation, shortened action potential duration, restored the irregular Ca<sup>2+</sup> transient and decreased the frequency of abnormal depolarisations in LQT8 hiPSC-CMs.[<sup><xref ref-type="bibr" rid="r10">10</xref>,<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r18">18</xref></sup>]</p>
<p>Furthermore, other inherited arrhythmias have been investigated using disease-specific hiPSC-CMs, including various types of LQTS – mutations in sodium voltage-gated channel alpha subunit 5 (<italic>SCN5A</italic>), potassium inwardly rectifying channel subfamily J member 2 (<italic>KCNJ2</italic>), calmodulin 1 (<italic>CALM1</italic>) or calmodulin 2 (<italic>CALM2</italic>), short QT syndrome (<italic>KCNH2</italic> mutation), Brugada syndrome type 1 (<italic>SCN5A</italic> mutation) and catecholaminergic polymorphic ventricular tachycardia (mutations in ryanodine receptor 2 (<italic>RYR2</italic>) or calsequestrin 2 [<italic>CASQ2]</italic>).[<sup><xref ref-type="bibr" rid="r19">19</xref>–<xref ref-type="bibr" rid="r40">40</xref></sup>] These cells recapitulated cellular electrophysiological changes in the heart of patients. <italic><xref ref-type="table" rid="tab1">Table 1</xref></italic> summarises the different studies that have used hiPSC-CMs as models to investigate inherited arrhythmias.</p>
</sec>
<sec>
<title>Human Induced Pluripotent Stem Cells for Modelling of Inherited Cardiomyopathies</title>
<p>In addition to inherited arrhythmias, there are some incidences of cardiomyopathies in families carrying specific genetic variant(s) that are responsible for causing the disease. Dilated cardiomyopathy (DCM) is a major type of cardiomyopathy that is characterised by systolic dysfunction and dilated cardiac chambers comprised of thin myocardial walls.[<sup><xref ref-type="bibr" rid="r41">41</xref></sup>] Most cases of DCM without any identifiable cause (e.g. coronary artery disease, systemic hypertension, viral infection) are diagnosed as ‘idiopathic’ DCM.</p>
<p>Based on family history and clinical findings, including sudden cardiac death, heart failure and abnormal echocardiography, previous clinical studies have proposed that familial transmission of idiopathic DCM is observed in 20–50% of patients.[<sup><xref ref-type="bibr" rid="r42">42</xref>–<xref ref-type="bibr" rid="r44">44</xref></sup>] When idiopathic DCM is identified in two or more family members, it is defined as familial DCM (FDC). FDC is largely caused by autosomal dominant mutations in key cardiac genes encoding sarcomere-related proteins, cytoskeletal proteins, mitochondrial proteins, nuclear membrane proteins and calcium regulators.[<sup><xref ref-type="bibr" rid="r43">43</xref>,<xref ref-type="bibr" rid="r45">45</xref>,<xref ref-type="bibr" rid="r46">46</xref></sup>] These loss-of-function mutations lead to the abnormal morphology and function of the heart that is seen in idiopathic DCM. Moreover, recently developed high-throughput gene analyses have revealed that inherited DCM is associated with mutations in more than 100 gene loci.[<sup><xref ref-type="bibr" rid="r47">47</xref></sup>]</p>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption>
<title>Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Models of Inherited Arrhythmias</title>
</caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease Phenotype</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Causal Genes (Mutations)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cellular Phenotypes in iPSC-CMs</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Drug Responses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="4" valign="top">LQT1</td>
<td align="left" colspan="1" rowspan="4" valign="top">LQT with broad-based T wave by reduced <italic>I</italic><sup>Ks</sup>, polymorphic ventricular tachycardia, often triggered by sympathetic activation (e.g. swim exercise, emotions)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNQ1</italic> (R190Q)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Ks</sup>, APD prolongation, irregular KCNQ1 localisation, increased susceptibility to isoproterenol-induced tachyarrhythmia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Isoproterenol-induced EAD was prevented by propranolol (beta-blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Morettin et al.[<sup><xref ref-type="bibr" rid="r9">9</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNQ1</italic> (exon 7 deletion)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Ks</sup>, APD prolongation, drug-induced FPD prolongation</td>
<td align="left" colspan="1" rowspan="1" valign="top">ML277 (K<sup>V</sup> channel activator) partially restored <italic>I</italic><sup>Ks</sup> and APD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Egashira et al.[<sup><xref ref-type="bibr" rid="r11">11</xref></sup>] Ma et al.[<sup><xref ref-type="bibr" rid="r12">12</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>KCNQ1</italic> (R594Q, R190Q)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduced <italic>I</italic><sup>Ks</sup> activation, APD prolongation, abnormal subcellular KCNQ1 R190Q localisation</td>
<td align="left" colspan="1" rowspan="1" valign="top">LUF7346 (hERG modulator) normalised <italic>I</italic><sup>Ks</sup> and APD</td>
<td align="left" colspan="1" rowspan="2" valign="top">Sala et al.[<sup><xref ref-type="bibr" rid="r16">16</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Isoproterenol-induced EAD was prevented by propranolol (beta-blocker)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4" valign="top">LQT2</td>
<td align="left" colspan="1" rowspan="4" valign="top">LQT with bifid T wave by reduced <italic>I</italic><sup>Kr</sup>, ventricular tachyarrhythmias triggered by sudden noise at rest; higher incidence in women</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNH2</italic> (A614V)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Kr</sup>, APD prolongation, EADs, triggered activity</td>
<td align="left" colspan="1" rowspan="1" valign="top">EADs were completely blocked by nifedipine (Ca<sup>2+</sup> blocker), abolished by pinacidil (K<sup>ATP</sup> channel agonist), inhibited by ranolazine (late <italic>I</italic><sup>Na</sup> inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Itzhaki et al.[<sup><xref ref-type="bibr" rid="r13">13</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNH2</italic> (R176W)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Kr</sup>, APD prolongation, EADs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypersensitivity to arrhythmogenic drugs including sotalol (beta-blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lahti et al.[<sup><xref ref-type="bibr" rid="r14">14</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNH2</italic> (G1681A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">APD/FPD prolongation</td>
<td align="left" colspan="1" rowspan="1" valign="top">EADs were induced by E4031 (hERG blocker), APD prolongation and EAD were reduced by nicorandil and PD118057 (hERG activators), isoproterenol-induced EADs were blocked by nadolol and propranolol (beta-blockers)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Matsa et al.[<sup><xref ref-type="bibr" rid="r15">15</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNH2</italic> (N006I)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Kr</sup>, APD prolongation</td>
<td align="left" colspan="1" rowspan="1" valign="top">LUF7346 (hERG modulator) normalised <italic>I</italic><sup>Ks</sup> and APD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sala et al.[<sup><xref ref-type="bibr" rid="r16">16</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4" valign="top">LQT3</td>
<td align="left" colspan="1" rowspan="4" valign="top">LQT with late peaking T wave by enhanced <italic>I</italic><sup>Na,L</sup>, lethal events often at rest</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (V240M, R535Q)</td>
<td align="left" colspan="1" rowspan="1" valign="top">APD prolongation, delayed <italic>I</italic><sup>Na</sup> time to peak and inactivation time</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fatima et al.[<sup><xref ref-type="bibr" rid="r20">20</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (V1763M)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced <italic>I</italic><sup>Na</sup>, APD prolongation</td>
<td align="left" colspan="1" rowspan="1" valign="top">The cellular phenotype was reversed by mexiletine (Na<sup>V</sup> blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ma et al.[<sup><xref ref-type="bibr" rid="r23">23</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (R1644H)</td>
<td align="left" colspan="1" rowspan="1" valign="top">APD prolongation, EADs, shorter <italic>I</italic><sup>Na</sup> inactivation time</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sodium current irregularities were rescued by mexiletine and ranolazine (Na<sup>V</sup> blockers)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Malan et al.[<sup><xref ref-type="bibr" rid="r24">24</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (F1473C)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>I</italic><sup>Na</sup> irregularities, delayed repolarisation, fatal arrhythmia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enhanced <italic>I</italic><sup>Na,L</sup> was reduced by increased pacing and mexiletine (Na<sup>V</sup> blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Terrenoire et al.[<sup><xref ref-type="bibr" rid="r26">26</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LQT3 (Overlap syndrome)</td>
<td align="left" colspan="1" rowspan="1" valign="top">LQT accompanied by bradycardia, conduction disease and/or Brugada syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (1795insD)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased <italic>I</italic><sup>Na</sup> density and upstroke velocity, APD prolongation, increased persistent <italic>I</italic><sup>Na</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Davis et al.[<sup><xref ref-type="bibr" rid="r19">19</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LQT7 (Andersen–Tawil syndrome)</td>
<td align="left" colspan="1" rowspan="1" valign="top">LQT accompanied by periodic paralysis, skeletal developmental abnormalities</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNJ2</italic> (R218W, R67W, R218Q)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irregular Ca<sup>2+</sup> release</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cellular phenotype was improved by flecainide and pilsicainide (Na<sup>V</sup> blockers) and KB-R7943 (<italic>I</italic><sup>NCX</sup> inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Kuroda et al.[<sup><xref ref-type="bibr" rid="r21">21</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">LQT8 (Timothy syndrome)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Dysfunction in multiple organs characterised by congenital cardiac defects, immune deficiency, autism and LQT with enhanced <italic>I</italic><sup>Ca,L</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CACNA1C</italic> (G1216A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">APD prolongation, DADs, abnormal Ca<sup>2+</sup> transients, irregular and slow contraction</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cellular phenotype was rescued by roscovitine (CDK5 inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yazawa et al.[<sup><xref ref-type="bibr" rid="r18">18</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CACNA1C</italic> (G406R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irregular contractions, excessive Ca<sup>2+</sup> influx, APD prolongation, irregular Ca<sup>2+</sup> transients</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ca<sup>2+</sup> defects and abnormal channel inactivation were improved by roscovitine (CDK5 inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yazawa et al.[<sup><xref ref-type="bibr" rid="r10">10</xref></sup>] and Song et al.[<sup><xref ref-type="bibr" rid="r17">17</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LQT14</td>
<td align="left" colspan="1" rowspan="1" valign="top">LQT associated with calmodulin-1 mutation enhancing <italic>I</italic><sup>Ca,L</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CALM1</italic> (F142L)</td>
<td align="left" colspan="1" rowspan="1" valign="top">QT prolongation, higher sensitivity to isoproterenol, altered rete dependency, defective <italic>I</italic><sup>Ca,L</sup> inactivation</td>
<td align="left" colspan="1" rowspan="1" valign="top">QT prolongation was reversed by verapamil (Ca<sup>2+</sup> blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rocchetti et al.[<sup><xref ref-type="bibr" rid="r25">25</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">LQT15</td>
<td align="left" colspan="1" rowspan="2" valign="top">LQT associated with calmodulin-2 mutation enhancing <italic>I</italic><sup>Ca,L</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CALM</italic> (D130G)</td>
<td align="left" colspan="1" rowspan="1" valign="top">APD prolongation, altered Ca<sup>2+</sup> transients, defective <italic>I</italic><sup>Ca,L</sup> inactivation, rescued by mutant gene suppression</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Limpitikul et al.[<sup><xref ref-type="bibr" rid="r22">22</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CALM2</italic> (N98S)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lower beating rate, APD prolongation, defective <italic>I</italic><sup>Ca,L</sup> inactivation, rescued by gene correction of mutant allele</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yamamoto et al.[<sup><xref ref-type="bibr" rid="r27">27</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Short QT syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">Shortened QT, sudden cardiac death</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>KCNH2</italic> (N588K)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased KCNH2 expression, increased <italic>I</italic><sup>Kr</sup> density, shortened APD, irregular and abnormal Ca<sup>2+</sup> transients, arrhythmic activity induced by carbachol (cholinergic activator)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Quinidine (multiple channel inhibitor) prolonged APD and carbachol-induced arrhythmias</td>
<td align="left" colspan="1" rowspan="1" valign="top">El-Battrawy et al.[<sup><xref ref-type="bibr" rid="r28">28</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">Brugada syndrome 1</td>
<td align="left" colspan="1" rowspan="3" valign="top">Coved-type ST elevation followed by a descending negative T wave in V1 to V3 on ECG, risk of malignant ventricular arrhythmias, reduced <italic>I</italic><sup>Na</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>PKP2</italic> (c.2484C&gt;T)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Na</sup> density, restored by wild-type gene expression</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerrone et al.[<sup><xref ref-type="bibr" rid="r29">29</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (R620H, R811H)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Na</sup> and maximal upstroke AP velocity, abnormal Ca<sup>2+</sup> transients, variable beating intervals</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Liang et al.[<sup><xref ref-type="bibr" rid="r30">30</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SCN5A</italic> (R367H)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced <italic>I</italic><sup>Na</sup> density</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Selga et al.[<sup><xref ref-type="bibr" rid="r31">31</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="9" valign="top">CPVT1</td>
<td align="left" colspan="1" rowspan="9" valign="top">Stress-induced ventricular tachyarrhythmias in structurally normal hearts</td>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>RYR2</italic> (F2483I)</td>
<td align="left" colspan="1" rowspan="2" valign="top">DADs, altered and irregular Ca<sup>2+</sup> transients, abnormal Ca<sup>2+</sup> response after cAMP-induced phosphorylation</td>
<td align="left" colspan="1" rowspan="1" valign="top">DADs were induced by isoproterenol</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fatima et al.[<sup><xref ref-type="bibr" rid="r32">32</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Abnormal Ca<sup>2+</sup> response after repolarisation was abolished by forskolin (adenylyl cyclase agonist)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>RYR2</italic> (M4109R)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Isoproterenol or forskolin (adrenergic stimulation)-enhanced DADs and triggered activity, EADs, irregular Ca<sup>2+</sup> transients</td>
<td align="left" colspan="1" rowspan="1" valign="top">DADs were eliminated by flecainide (Na<sup>V</sup> blocker) and thapsigargin (SERCA inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Itzhaki et al.[<sup><xref ref-type="bibr" rid="r33">33</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Irregular Ca<sup>2+</sup> transients was improved by propranolol (beta-blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>RYR2</italic> (S406L)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Isoproterenol-induced diastolic Ca<sup>2+</sup> elevation, reduced SR Ca<sup>2+</sup> content, DADs, increased frequency and duration of Ca<sup>2+</sup> release, arrhythmias</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dantrolene (RyR inhibitor) restored normal Ca<sup>2+</sup> spark properties and rescued the arrhythmogenic phenotype</td>
<td align="left" colspan="1" rowspan="1" valign="top">Jung et al.[<sup><xref ref-type="bibr" rid="r34">34</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>RYR2</italic> (P2328S)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Abnormal Ca<sup>2+</sup> transients, EADs, reduced SR Ca<sup>2+</sup> content, increased non-alternating variability of Ca<sup>2+</sup> transients in response to isoproterenol and adrenaline, decreased AP upstroke velocity</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Jung et al.,[<sup><xref ref-type="bibr" rid="r34">34</xref></sup>] Kujala et al.[<sup><xref ref-type="bibr" rid="r35">35</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>RYR2</italic> (R420Q)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Less developed ultrastructure, isoproterenol-induced arrhythmias and increased diastolic Ca<sup>2+</sup> levels</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Novak et al.[<sup><xref ref-type="bibr" rid="r37">37</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>RYR2</italic> (L3741P)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Altered Ca<sup>2+</sup> transients, low SR Ca<sup>2+</sup> content, Ca<sup>2+</sup> leak, isoproterenol-induced irregular Ca<sup>2+</sup> waves, prolonged Ca<sup>2+</sup> sparks and DADs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cellular phenotype was rescued by flecainide (Na<sup>V</sup> blocker)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preininger et al.[<sup><xref ref-type="bibr" rid="r39">39</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>RYR2</italic> (I4587V)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased diastolic Ca<sup>2+</sup> waves, pacing-induced DADs</td>
<td align="left" colspan="1" rowspan="1" valign="top">S107 (RyR2 stabiliser) reduced DADs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sasaki et al.[<sup><xref ref-type="bibr" rid="r40">40</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">CPVT2</td>
<td align="left" colspan="1" rowspan="2" valign="top">Stress-induced ventricular tachyarrhythmias in structurally normal hearts</td>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>CASQ2</italic> (D307H)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Isoproterenol-induced DADs, EADs, oscillatory arrhythmic prepotentials, increased diastolic intracellular Ca<sup>2+</sup> levels, irregular Ca<sup>2+</sup> transients, reduced threshold for store overload-induced Ca<sup>2+</sup> release, myofibril disorganisation, SR abnormalities, reduced caveolae</td>
<td align="left" colspan="1" rowspan="1" valign="top">Propranolol, carvedilol (beta-blockers), riluzole and flecainide (Na<sup>V</sup> blockers) inhibited isoproterenol-induced arrhythmia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Jung et al.[<sup><xref ref-type="bibr" rid="r34">34</xref></sup>] Maizels et al.[<sup><xref ref-type="bibr" rid="r36">36</xref></sup>] Novak et al.[<sup><xref ref-type="bibr" rid="r37">37</xref>,<xref ref-type="bibr" rid="r38">38</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">JTB-519 (RyR stabiliser) and carvedilol suppressed abnormal Ca<sup>2+</sup> cycling</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>AP = action potential; APD = action potential duration; CACNA1C = calcium voltage-gated channel subunit alpha1 C; CALM1 = calmodulin 1; CALM2 = calmodulin 2; cAMP = cyclic adenosine monophosphate; CASQ2 = calsequestrin 2; CDK5 = cyclin-dependent kinase 5; CM = cardiomyocyte; CPVT = catecholaminergic polymorphic ventricular tachycardia; DAD = delayed afterdepolarisation; EAD = early afterdepolarisation; FPD = field potential duration; hERG = pore-forming subunit of rapidly activating delayed rectifier potassium channel; iPSC-CM = induced pluripotent stem cell-derived cardiomyocyte; I<sup>Ca,L</sup> = voltage-gated L-type calcium channel current; I<sup>Kr</sup> = rapid delayed rectifier potassium current; I<sup>Ks</sup> = slow delayed rectifier potassium current; I<sup>Na</sup> = sodium current; I<sup>Na,L</sup> = late sodium current; I<sup>NCX</sup> = sodium-calcium exchanger current; KCNH2 = potassium voltage-gated channel subfamily H member 2; KCNQ1 = potassium voltage-gated channel subfamily Q member 1; K<sup>V</sup> = voltage-gated potassium channel; LQT = long QT; N/A = not applicable; Na<sup>V</sup> = voltage-gated sodium channel; PKP2 = plakophilin 2; RyR2 = ryanodine receptor 2; SCN5A = sodium voltage-gated channel alpha subunit 5; SERCA = sarcoplasmic/endoplasmic reticulum calcium ATPase; SR = sarcoplasmic reticulum.</p>
</table-wrap-foot>
</table-wrap>
<p>Although the pathophysiology of FDC is heterogeneous, the effect of each individual mutation has been unclear in the context of FDC. To address this, human CMs are ideal for<italic> in vitro</italic> functional analysis of mutations associated with FDC, but, as mentioned earlier, it is difficult to acquire a renewable source of cardiac cells. Compared with animal models and non-CMs expressing DCM mutant proteins, hiPSC-CMs are expected to exhibit responses similar to those observed in native human myocardium. For example, individual families carry a mutation that causes an arginine-to-tryptophan substitution at amino acid position 173 in the cardiac troponin T (cTnT) protein.[<sup><xref ref-type="bibr" rid="r48">48</xref></sup>] Patient-specific hiPSCs were produced using minimally invasive procedures from skin fibroblasts of family members, and hiPSC-CMs were generated and tested to investigate the mechanisms underlying FDC. The FDC hiPSC-CMs exhibited reduced Ca<sup>2+</sup> influx and contractility, despite normal electrophysiological properties. These cells also showed the characteristic patchy structure of myofilaments, which was enhanced upon noradrenaline stimulation and stretching, leading to systolic dysfunction.[<sup><xref ref-type="bibr" rid="r48">48</xref></sup>]</p>
<p>This is consistent with the fact that the tendency towards DCM is enhanced by increases in inotropic effects and hypertension. These findings explain the involvement of cTnT dysfunction in the development of DCM. Thus, FDC hiPSC-CMs recreate, at least in part, the pathophysiology of FDC in human patients. Other causal gene mutations responsible for inherited cardiomyopathies, including DCM, hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy/dysplasia, have been reported.[<sup><xref ref-type="bibr" rid="r49">49</xref>–<xref ref-type="bibr" rid="r57">57</xref></sup>] <italic><xref ref-type="table" rid="tab2">Table 2</xref></italic> lists studies that have used hiPSC-CMs as models for investigating inherited cardiomyopathies.</p>
<p>Although numerous studies have summarised the characteristic features of familial heart diseases using patient-specific hiPSC-CMs, as described above, it is still challenging to fully recapitulate the disease phenotype using iPSC-CM-based disease modelling, primarily because hiPSC-CMs exhibit immature functions and morphology. For example, an incomplete ion channel profile (e.g. lack of <italic>I</italic><sub>K1</sub>, corresponding to slower action potential kinetics and a relatively positive diastolic potential) and subcellular structure (e.g. the absence of or underdeveloped T-tubule and sarcomere formation) are commonly observed in hiPSC-CMs.[<sup><xref ref-type="bibr" rid="r58">58</xref>–<xref ref-type="bibr" rid="r60">60</xref></sup>] The gene expression profile of hiPSC-CMs also resembles that of foetal CMs and is distinct from that of adult CMs.[<sup><xref ref-type="bibr" rid="r60">60</xref>,<xref ref-type="bibr" rid="r61">61</xref></sup>] The immaturity of hiPSC-CMs in terms of function and gene expression profile may result in controversial findings, particularly in the investigation of late-onset cardiac diseases that largely require adult CM-like cells for disease modelling.</p>
<p>In an <italic>in vitro</italic> study using hiPSC-CMs to investigate the pathophysiology of late-onset Pompe disease, which is characterised by slow progression of muscle weakness, although patient-specific hiPSC-CMs exhibited typical features associated with the disease, such as intracellular glycogen accumulation and mitochondrial dysfunction, they did not fully exhibit the autophagic abnormalities that are observed <italic>in vivo</italic>.[<sup><xref ref-type="bibr" rid="r62">62</xref>,<xref ref-type="bibr" rid="r63">63</xref></sup>] This may be overcome by using fully differentiated hiPSC-CMs assembled along with a complete subcellular system for muscle contraction, Ca<sup>2+</sup> cycling, metabolism and protein recycling. Recent studies have contributed to the development of protocols for the maturation of hiPSC-CMs using electrical and/or mechanical stimulation, a 3D culture system with scaffold materials, coculture with fibroblasts or CMs <italic>in vitro</italic> and <italic>in vivo</italic> and a combination of these techniques, leading to improvement in contractility, Ca<sup>2+</sup> handling and electrophysiological properties.[<sup><xref ref-type="bibr" rid="r64">64</xref>–<xref ref-type="bibr" rid="r68">68</xref></sup>]</p>
<p>Lack of chamber-specific characteristics is another major concern regarding the use of hiPSC-CMs for disease modelling. As the structure, haemodynamic stress, developmental origin and protein expression profile are quite distinctive among the cardiac chambers,[<sup><xref ref-type="bibr" rid="r59">59</xref>,<xref ref-type="bibr" rid="r69">69</xref>,<xref ref-type="bibr" rid="r70">70</xref></sup>] the molecular features of individual CMs in each chamber would also differ. Some inherited arrhythmias and cardiomyopathies have chamber-specific characteristics. Clinical phenotypes of Brugada syndrome and ARVC/D likely originate from the right ventricular outflow tract. However, disease models based on hiPSC-CMs may not fully recapitulate the characteristic features of any specific region of the heart.</p>
<p>A differentiated hiPSC-CM cluster usually consists of electrophysiologically heterogeneous subtypes including ventricular-, atrial- and nodal-like myocytes. The ventricular-like hiPSC-CMs exhibit properties analogous to those of human ventricular myocytes (e.g. steep upstroke (Phase 0) and plateau phase (Phase 4) of action potentials), whereas the nodal-type hiPSC-CMs exhibit slower action potential kinetics and depolarising diastolic potential.[<sup><xref ref-type="bibr" rid="r71">71</xref></sup>] This mixed subtype of hiPSC-CMs leads to a wide range of results rather than being representative of a specific subtype of CMs. The development of protocols for subtype-specific and/or chamber-specific differentiation of hiPSC-CMs will accelerate research to identify the chamber-specific phenotypes associated with heart diseases. Although some genetic heart diseases are rare, many of them lead to life-threatening conditions. Therefore, further intensive research using disease-specific hiPSC-CMs should be promoted to gain insights into the underlying mechanisms and to identify potential therapeutic targets of these genetic diseases in order to develop novel therapeutic approaches for individual patients.</p>
</sec>
<sec>
<title>Human Induced Pluripotent Stem Cells as a Tool for Drug Screening</title>
<p>Currently, the development of new drugs requires multiple processes, including screening of numerous putative drug compounds based on chemical structure and <italic>in vitro</italic> assays of pharmacological activity, followed by analyses of pharmacokinetics and safety <italic>in vitro</italic> and <italic>in vivo</italic> and, finally, clinical trials in humans. In most cases, these processes take many years until the candidate compounds are tested in humans.[<sup><xref ref-type="bibr" rid="r72">72</xref></sup>] Even though the effectiveness of compounds may be promising in cell culture and animal experiments, problems identified in clinical trials assessing the effects of these compounds on the QT interval (known as a thorough QT/QTc study) following pharmacokinetics examination in humans may halt the further development of these compounds. However, if human cardiac cells were widely available, drug testing in human CMs might provide effective and safe drug candidates rapidly and economically, because the response to compounds tested using <italic>in vitro</italic> experiments with human CMs could resemble that of the human body.</p>
<table-wrap id="tab2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption>
<title>Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Models of Inherited Cardiomyopathies</title>
</caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease phenotype</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Causal genes (mutations)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cellular phenotypes</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Drug responses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">DCM</td>
<td align="left" colspan="1" rowspan="2" valign="top">Dilation and impaired contraction of LV or both ventricles presenting various arrhythmias, leading to sudden death</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>TNNT2</italic> (R173W)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced contraction force, compromised contraction, sarcomeric structural irregularities, reduced beating rate, abnormal Ca<sup>2+</sup> transients, abnormal sarcomeric alpha-actinin distribution</td>
<td align="left" colspan="1" rowspan="1" valign="top">Metoprolol (beta-blocker) improved abnormal functions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Grunig et al.[<sup><xref ref-type="bibr" rid="r44">44</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>DES</italic> (A285V)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse abnormal desmin aggregations, diminished Ca<sup>2+</sup> reuptake, reduced beating rate, failed sustained response to isoproterenol</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Morita et al.[<sup><xref ref-type="bibr" rid="r45">45</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">HCM</td>
<td align="left" colspan="1" rowspan="3" valign="top">Thickened LV causing diastolic dysfunction</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>MYH7</italic> (R663H)</td>
<td align="left" colspan="1" rowspan="1" valign="top">hiPSC-CM hypertrophy, elevated intracellular Ca<sup>2+</sup> levels, irregular Ca<sup>2+</sup> transients</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myocyte hypertrophy, Ca<sup>2+</sup> handling abnormalities and arrhythmia were rescued by verapamil and diltiazem (Ca<sup>2+</sup> blockers)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sun et al.[<sup><xref ref-type="bibr" rid="r48">48</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>LMNA</italic> (R225X, Q354X, T518fs, c.50-51insGCCA)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Nuclear bleb formation, micronucleation, nuclear senescence, electrical stimulation-induced cellular apoptosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">U0126 and selumetinib (AZD6244; ERK1/2 and MEK1/2 inhibitors) attenuated electric stimulation-induced proapoptotic effects</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tse et al.,[<sup><xref ref-type="bibr" rid="r49">49</xref></sup>] Carvajal-Vergara et al.[<sup><xref ref-type="bibr" rid="r50">50</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nuclear blebbing and electrical stimulation-induced apoptosis in R225X iPSC-CMs were rescued by PTC124 (ataluren, promoting read-through of the premature stop codon)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HCM (Leopard syndrome)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited disease characterised by skin, facial and cardiac anomalies</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>PTPN11</italic> (T426M)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CM hypertrophy, NFATC4 nuclear accumulation, increased Ras/MAPK phosphorylation</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mestroni et al.[<sup><xref ref-type="bibr" rid="r46">46</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HCM (Pompe disease)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypotonia and signs of heart failure by the age of 3–5 months; accumulation of membrane-bound and cytoplasmic glycogen and rupture of lysosomes, aberrant mitochondria, accumulation of autophagic vesicles leading to cardiomyopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>GAA</italic> (C1935A/C1935A, C1935A/G2040+1T, G1062G/C1935A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glycogen accumulation, abnormal mitochondria ultrastructure, accumulation of autophagosomes, cellular respiration irregularities</td>
<td align="left" colspan="1" rowspan="1" valign="top">rhGAA enzyme and 2-3-methyladenine (autophagy inhibitor) normalised glycogen content; 3-<sc>l</sc>-carnitine increased O<sup>2</sup> consumption and suppressed mitochondrial structural phenotype</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dellefave et al.[<sup><xref ref-type="bibr" rid="r47">47</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ARVC/D</td>
<td align="left" colspan="1" rowspan="1" valign="top">Desmosomal dysfunction; ventricular arrhythmias; fatty or fibrofatty replacement of myocardium with thinning of the RV wall</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>PKP2</italic> (c.972InsT/N, A324fs335X)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced density of PKP2, plakoglobin and connexin-43, FPD prolongation, widened and distorted desmosomes, lipid droplet clusters, increased lipid content in adipogenic differentiation media</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lipid accumulation was prevented by 6-bromoindirubin-3¢-oxime (glycogen synthase kinase-3-beta inhibitor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Huang et al.[<sup><xref ref-type="bibr" rid="r51">51</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>PKP2</italic> (c.2484C&gt;T, c.2013delC)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irregular PKP2 nuclear accumulation, diminished beta-catenin activity in cardiogenic conditions, abnormal PPAR-gamma activation, Ca<sup>2+</sup> handling defects</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lan et al.[<sup><xref ref-type="bibr" rid="r52">52</xref></sup>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>PKP2</italic> (L614P)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduced expression of PKP2 and plakoglobin, disorganised myofibrils, increased lipid content in adipogenic differentiation media</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lee et al.[<sup><xref ref-type="bibr" rid="r53">53</xref></sup>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>ARVC/D = arrhythmogenic right ventricular cardiomyopathy/dysplasia; CM = cardiomyocyte; DCM = dilated cardiomyopathy; DES = desmin; ERK = extracellular signal-regulated kinase; FPD = field potential duration</italic>; GAA = <italic>acid alpha-glucosidase; HCM = hypertrophic cardiomyopathy; hiPSC-CM = human induced pluripotent stem cell-derived cardiomyocyte;</italic> LMNA, <italic>lamin A/C; LV = left ventricle; MAPK = mitogen-activated protein kinase; MEK = mitogen-activated protein kinase kinase;</italic> MYH7 = <italic>myosin heavy chain 7; N/A = not applicable; NFATC4 = nuclear factor of activated T cells cytoplasmic 4;</italic> PKP2 = <italic>plakophilin 2; PPAR-gamma = peroxisome proliferator-activated receptor-gamma;</italic> PTPN11 = <italic>protein tyrosine phosphatase non-receptor type 11; rh = recombinant human; RV = right ventricle; TNNT2 = troponin T2, cardiac type.</italic></p>
</table-wrap-foot>
</table-wrap>
<p>Disease-specific hiPSC-derived CMs potentially exhibit similar physiological characteristics as diseased cells in patients, and may be a useful tool to predict the benefits and side-effects of drug candidates in patients. Drug screening using hiPSC-CMs to detect side effects such as drug-induced QT prolongation and ventricular tachyarrhythmias could contribute to the early withdrawal of therapeutic compounds with undesirable cardiac effects before the initiation of <italic>in vivo</italic> experiments and clinical trials.[<sup><xref ref-type="bibr" rid="r72">72</xref>,<xref ref-type="bibr" rid="r73">73</xref></sup>] Other than the development of new drugs, the cardiac side effects of some already marketed drugs, including anti-arrhythmic drugs and non-cardiac drugs such as antihistamines, antipsychotics and anti-infective drugs, have been widely recognised. These drugs have the potential to cause torsade de pointes, in combination with other endogenous and environmental factors.[<sup><xref ref-type="bibr" rid="r73">73</xref></sup>] Drug testing using hiPSC-CMs may also be applicable in this context.</p>
<p>Although hiPSC-CMs share some characteristics with adult human ventricular myocytes, hiPSC-CMs are commonly known to exhibit the features of foetal ‘immature’ CMs in terms of their gene expression profile, structure and electrophysiology, as noted above. hiPSC-CMs express cardiac-specific genes (e.g. those encoding cTnT, alpha-myosin heavy chain) and exhibit ion channel activity (e.g. similar <italic>I</italic><sub>Na</sub>, <italic>I</italic><sub>Kr</sub> and <italic>I</italic><sub>Ca,L</sub> current density to that in adult ventricular CMs);[<sup><xref ref-type="bibr" rid="r12">12</xref>–<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r16">16</xref>,<xref ref-type="bibr" rid="r71">71</xref>,<xref ref-type="bibr" rid="r74">74</xref>–<xref ref-type="bibr" rid="r83">83</xref></sup>] however, morphologically they are more rounded or multiangular in shape and smaller in size, with disorganised myofibrils and a lack of t-tubules, which contribute to the slower kinetics of the Ca<sup>2+</sup> transient.[<sup><xref ref-type="bibr" rid="r38">38</xref>,<xref ref-type="bibr" rid="r76">76</xref>,<xref ref-type="bibr" rid="r83">83</xref>–<xref ref-type="bibr" rid="r87">87</xref></sup>] These important differences should be considered when using hiPSC-CMs in drug screening. Further investigations are needed to develop optimal methods for more efficient differentiation into functional CMs that exhibit the typical properties of adult CMs.</p>
</sec>
<sec>
<title>Gene Editing to Create Disease-Specific Human Induced Pluripotent Stem Cells</title>
<p>Comprehensive genetic studies have identified causal mutations responsible for genetic heart diseases. hiPSC-CMs have emerged as a highly effective tool for modelling such diseases. Although it is technically possible to induce disease-specific hiPSC-CMs, patient-derived somatic cells may not be readily available, especially in the case of rare diseases. In addition, interclonal variation is seen among hiPSC clones, resulting from different genetic backgrounds associated with individual cells.</p>
<p>Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) 9 is a gene-editing technology that can solve the challenges associated with the genetic variability.[<sup><xref ref-type="bibr" rid="r88">88</xref>,<xref ref-type="bibr" rid="r89">89</xref></sup>] CRISPR is a DNA sequence found in bacterial genomes; it is thought to be derived from viruses, is known to protect bacteria from repeated viral infections and acts as a basic adaptive immune system for prokaryotes. Cas9 is a DNA-cutting enzyme that recognises CRISPR sequences and causes site-specific DNA double-strand breaks (<italic><xref ref-type="fig" rid="fig2">Figure 2</xref></italic>). Recent advances in CRISPR/Cas9-based gene editing have markedly improved the efficiency and specificity of the method and expanded its applications, including knockout, repression and activation of genes of interest.[<sup><xref ref-type="bibr" rid="r90">90</xref></sup>]</p>
<p>In phenotypic analysis of monogenic inherited diseases, this technology is also applicable to either disease-associated mutagenesis in wild-type hiPSCs or to the correction of pathogenic gene mutations in disease-specific hiPSCs (<italic><xref ref-type="fig" rid="fig3">Figure 3</xref></italic>).[<sup><xref ref-type="bibr" rid="r89">89</xref></sup>] Analysis of disease-specific hiPSCs versus wild-type hiPSCs established from healthy donor cells as a control may result in unreliable outcomes due to the different genetic backgrounds of the disease-specific hiPSCs and control cells. However, CRISPR/Cas9-based gene editing enables the preparation of an isogenic control by normalising a disease-relevant mutation in disease-specific hiPSCs or by inducing the mutation in wild-type hiPSCs so that diseased and control cells with the same genetic background are obtained. In addition, CRISPR/Cas9-based gene editing could allow the production of isogenic cells with intact and/or corrected variant alleles in non-coding regions including enhancers that may reveal the role of mutations in the transcriptional regulation of genes responsible for a disease phenotype. This method shows promise for the proper evaluation of the involvement of mutated genes in disease phenotype following <italic>in vitro</italic> differentiation (<italic><xref ref-type="fig" rid="fig3">Figure 3</xref></italic>).</p>
<fig id="fig2" orientation="portrait" position="float">
<label>Figure 2:</label>
<caption>
<title>Principle of Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-associated (Cas) 9-Based Gene Editing</title>
</caption>
<graphic xlink:href="ecr-15-2-g002"></graphic>
<p>NGG = protospacer-adjacent motif (N can be any nucleotide base).</p>
</fig>
<fig id="fig3" orientation="portrait" position="float">
<label>Figure 3:</label>
<caption>
<title>Gene Editing in Human Induced Pluripotent Stem Cell for Cardiac Applications</title>
</caption>
<graphic xlink:href="ecr-15-2-g003"></graphic>
<p>iPSC = induced pluripotent stem cell.</p>
</fig>
<p>Polygenic diseases, which differ from monogenic inherited diseases in that more than one gene is involved in their dysfunction, impose another limitation on the use of hiPSCs. Polygenic diseases are thought to be caused by a combination of multiple mutations, each of which has a small effect, with or without extrinsic factors. Although gene editing has been used to edit multiple regions of the genome, a major challenge towards using hiPSCs to investigate polygenic diseases is identification of the corresponding mutations and understanding how each mutation contributes to the pathogenesis of these multifactorial diseases. Moreover, in some cases, environmental factors may strongly affect disease phenotypes, making experimental conditions and further analysis more complicated. Comprehensive reviews are available for detailed information regarding the use of gene editing in iPSC research.[<sup><xref ref-type="bibr" rid="r89">89</xref>,<xref ref-type="bibr" rid="r91">91</xref></sup>]</p>
</sec>
<sec>
<title>Consideration of Human Induced Pluripotent Stem Cells for Application in Disease Modelling and Clinical Use</title>
<p>Despite extensive benefits, there are still many unsolved issues regarding the use of hiPSCs in further applications. One of the major issues is that the quality of individual hiPSC lines is variable, even when an hiPSC line is derived from one individual. Classical iPSC reprogramming methods using retroviral or lentiviral vectors may cause random insertional mutations in the host genome, resulting in alteration of subsequent cell phenotypes.[<sup><xref ref-type="bibr" rid="r92">92</xref></sup>]</p>
<p>Recent advances in reprogramming strategies using non-integrating, virus-free and vector-free methods are overcoming this issue.[<sup><xref ref-type="bibr" rid="r93">93</xref>,<xref ref-type="bibr" rid="r94">94</xref></sup>] However, it is still technically difficult to eliminate the risk of gene mutations during the reprogramming process because forced expression of reprogramming factors can induce DNA damage.[<sup><xref ref-type="bibr" rid="r95">95</xref></sup>] In fact, protein-coding point mutations acquired during or after reprogramming were identified in multiple hiPSC lines, some of which exhibit unpredictable phenotypes.[<sup><xref ref-type="bibr" rid="r96">96</xref></sup>] Thus, accumulating evidence regarding the mechanism underlying the reprogramming of iPSCs is expected to provide insights into how the quality of hiPSC lines may be stabilised and standardised for use as a cell source for further experiments and clinical application.</p>
<p>Precise investigations into the pathophysiology of inherited diseases using patient-derived iPSCs require improved protocols that allow highly efficient differentiation of hiPSCs into a specific cell type, because the differentiation efficiency in current experiments remains significantly lower than what is desired. The characteristic variability of cells differentiated from disease-specific hiPSCs is a considerable hurdle that research into pathophysiology must overcome. Epigenetic modifications are presumably one of the causes of phenotype variability. Optimised sorting methods to collect only a desired cell type from the heterogeneous cell population need to be developed. Current research efforts are advancing cardiac differentiation protocols to generate spontaneously beating CM-like cell clusters, but the clusters of differentiated cells that are heterogeneous also contain other mesodermal derivatives, such as smooth muscle cells and endothelial cells, as well as undifferentiated cells, which may increase the risk of tumourigenesis.</p>
<p>Pathophysiological studies using disease-specific hiPSCs allow us to determine the cellular characteristics of a disease, but do not recreate the function of the whole organ within the body. Although complex bioengineering approaches, such as organoid formation and 3D culture systems, are available,[<sup><xref ref-type="bibr" rid="r97">97</xref>,<xref ref-type="bibr" rid="r98">98</xref></sup>] it is difficult to use these methods in the heart because CMs in the heart are predominantly situated in a highly organised structure comprising vessels, nerves, mesenchymal cells, extracellular matrix and myocytes. In addition, CMs are continuously exposed to dynamically changing neuroendocrine factors and mechanical stresses. Therefore, it should be considered that studies using disease-specific hiPSC-CMs fundamentally provide simplified information regarding the pathophysiology in patients with a familial disease. Nevertheless, the experimental data from these cells may reveal responses that mirror actual phenomena in human patients, and are thus valuable for gaining an understanding of the inherited disease.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Disease-specific hiPSC-CMs, which carry the same genomic information as patients with inherited diseases, can undoubtedly be of use in research to address the pathophysiology of monogenic inherited diseases, the drug responsiveness of patients for personalised medicine and drug development by providing a cell source for screening compounds and drug safety testing. A combination of disease-specific hiPSC-CMs and gene-editing technologies may further advance our understanding of genetic diseases and drug development in cardiovascular medicine.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors thank Steven H DeVries (Ophthalmology &amp; Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, US) for helpful suggestions during writing of the manuscript. The authors also thank all members of the Laboratory of Stem Cell and Regenerative Medicine for helpful discussions.</p>
</ack>
<ref-list>
<ref id="r1">
<label>1.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<fpage>861</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id>
<pub-id pub-id-type="pmid">18035408</pub-id>
</element-citation>
</ref>
<ref id="r2">
<label>2.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>663</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id>
<pub-id pub-id-type="pmid">16904174</pub-id>
</element-citation>
</ref>
<ref id="r3">
<label>3.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vodyanik</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Smuga-Otto</surname>
<given-names>K</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Induced pluripotent stem cell lines derived from human somatic cells</article-title>
<source/>Science
          <year>2007</year>
<volume>318</volume>
<fpage>1917</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1126/science.1151526</pub-id>
<pub-id pub-id-type="pmid">18029452</pub-id>
</element-citation>
</ref>
<ref id="r4">
<label>4.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>West</surname>
<given-names>JA</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Reprogramming of human somatic cells to pluripotency with defined factors</article-title>
<source/>Nature
          <year>2008</year>
<volume>451</volume>
<fpage>141</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1038/nature06534</pub-id>
<pub-id pub-id-type="pmid">18157115</pub-id>
</element-citation>
</ref>
<ref id="r5">
<label>5.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A decade of transcription factor-mediated reprogramming to pluripotency</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2016</year>
<volume>17</volume>
<fpage>183</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1038/nrm.2016.8</pub-id>
<pub-id pub-id-type="pmid">26883003</pub-id>
</element-citation>
</ref>
<ref id="r6">
<label>6.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lengerke</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Patient-specific pluripotent stem cells: promises and challenges</article-title>
<source/>Nat Rev Endocrinol
          <year>2009</year>
<volume>5</volume>
<fpage>195</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2009.18</pub-id>
<pub-id pub-id-type="pmid">19352317</pub-id>
</element-citation>
</ref>
<ref id="r7">
<label>7.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Greenhough</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Modelling human disease with pluripotent stem cells</article-title>
<source/>Curr Gene Ther
          <year>2013</year>
<volume>13</volume>
<fpage>99</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.2174/1566523211313020004</pub-id>
<pub-id pub-id-type="pmid">23444871</pub-id>
</element-citation>
</ref>
<ref id="r8">
<label>8.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rajamohan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>E</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation</article-title>
<source/>Eur Heart J
          <year>2011</year>
<volume>32</volume>
<fpage>952</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehr073</pub-id>
<pub-id pub-id-type="pmid">21367833</pub-id>
</element-citation>
</ref>
<ref id="r9">
<label>9.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bellin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Welling</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific induced pluripotent stem-cell models for long-QT syndrome</article-title>
<source/>N E
          <source/>ngl J Med
          <year>2010</year>
<volume>363</volume>
<fpage>1397</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0908679</pub-id>
<pub-id pub-id-type="pmid">20660394</pub-id>
</element-citation>
</ref>
<ref id="r10">
<label>10.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hsueh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>230</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1038/nature09855</pub-id>
<pub-id pub-id-type="pmid">21307850</pub-id>
</element-citation>
</ref>
<ref id="r11">
<label>11.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egashira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yuasa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Disease characterization using LQTS-specific induced pluripotent stem cells</article-title>
<source/>Cardiovasc Res
          <year>2012</year>
<volume>95</volume>
<fpage>419</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvs206</pub-id>
<pub-id pub-id-type="pmid">22739119</pub-id>
</element-citation>
</ref>
<ref id="r12">
<label>12.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Stem Cell Res Ther
          <year>2015</year>
<volume>6</volume>
<fpage>39</fpage>
<pub-id pub-id-type="doi">10.1186/s13287-015-0027-z</pub-id>
<pub-id pub-id-type="pmid">25889101</pub-id>
</element-citation>
</ref>
<ref id="r13">
<label>13.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modelling the long QT syndrome with induced pluripotent stem cells</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>225</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/nature09747</pub-id>
<pub-id pub-id-type="pmid">21240260</pub-id>
</element-citation>
</ref>
<ref id="r14">
<label>14.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahti</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kujala</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture</article-title>
<source/>Dis Model Mech
          <year>2012</year>
<volume>5</volume>
<fpage>220</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.008409</pub-id>
<pub-id pub-id-type="pmid">22052944</pub-id>
</element-citation>
</ref>
<ref id="r15">
<label>15.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Medway</surname>
<given-names>C</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes</article-title>
<source/>Eur Heart J
          <year>2014</year>
<volume>35</volume>
<fpage>1078</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/eht067</pub-id>
<pub-id pub-id-type="pmid">23470493</pub-id>
</element-citation>
</ref>
<ref id="r16">
<label>16.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sala</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ward-van Oostwaard</surname>
<given-names>D</given-names>
</name>
</person-group>
<etal></etal>
<article-title>A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells</article-title>
<source/>EMBO Mol Med
          <year>2016</year>
<volume>8</volume>
<fpage>1065</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201606260</pub-id>
<pub-id pub-id-type="pmid">27470144</pub-id>
</element-citation>
</ref>
<ref id="r17">
<label>17.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Isseroff</surname>
<given-names>Y</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Inhibition of CDK5 alleviates the cardiac phenotypes in Timothy syndrome</article-title>
<source/>Stem Cell Rep
          <year>2017</year>
<volume>9</volume>
<fpage>50</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.05.028</pub-id>
<pub-id pub-id-type="pmid">28648896</pub-id>
</element-citation>
</ref>
<ref id="r18">
<label>18.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dolmetsch</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Modeling Timothy syndrome with iPS cells</article-title>
<source/>J Cardiovasc Transl Res
          <year>2013</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s12265-012-9444-x</pub-id>
<pub-id pub-id-type="pmid">23299782</pub-id>
</element-citation>
</ref>
<ref id="r19">
<label>19.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>CW</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease</article-title>
<source/>Circulation
          <year>2012</year>
<volume>125</volume>
<fpage>3079</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.066092</pub-id>
<pub-id pub-id-type="pmid">22647976</pub-id>
</element-citation>
</ref>
<ref id="r20">
<label>20.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaifeng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dittmann</surname>
<given-names>S</given-names>
</name>
</person-group>
<etal></etal>
<article-title>The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e83005</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0083005</pub-id>
<pub-id pub-id-type="pmid">24349418</pub-id>
</element-citation>
</ref>
<ref id="r21">
<label>21.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuroda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yuasa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen–Tawil syndrome-iPS cell-derived cardiomyocytes</article-title>
<source/>Biochem Biophys Rep
          <year>2017</year>
<volume>9</volume>
<fpage>245</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrep.2017.01.002</pub-id>
<pub-id pub-id-type="pmid">28956012</pub-id>
</element-citation>
</ref>
<ref id="r22">
<label>22.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Limpitikul</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<etal></etal>
<article-title>A precision medicine approach to the rescue of function on malignant calmodulinopathic long-QT syndrome</article-title>
<source/>Circ Res
          <year>2017</year>
<volume>120</volume>
<fpage>39</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309283</pub-id>
<pub-id pub-id-type="pmid">27765793</pub-id>
</element-citation>
</ref>
<ref id="r23">
<label>23.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells</article-title>
<source/>Int J Cardiol
          <year>2013</year>
<volume>168</volume>
<fpage>5277</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2013.08.015</pub-id>
<pub-id pub-id-type="pmid">23998552</pub-id>
</element-citation>
</ref>
<ref id="r24">
<label>24.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stallmeyer</surname>
<given-names>B</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction</article-title>
<source/>Basic Res Cardiol
          <year>2016</year>
<volume>111</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1007/s00395-016-0530-0</pub-id>
<pub-id pub-id-type="doi">10.1007/s00395-016-0530-0</pub-id>
<pub-id pub-id-type="pmid">26803770</pub-id>
</element-citation>
</ref>
<ref id="r25">
<label>25.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocchetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dreizehnter</surname>
<given-names>L</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Cardiovasc Res
          <year>2017</year>
<volume>113</volume>
<fpage>531</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvx006</pub-id>
<pub-id pub-id-type="pmid">28158429</pub-id>
</element-citation>
</ref>
<ref id="r26">
<label>26.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrenoire</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>KW</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</article-title>
<source/>J Gen Physiol
          <year>2012</year>
<volume>141</volume>
<fpage>61</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1085/jgp.201210899</pub-id>
<pub-id pub-id-type="pmid">23277474</pub-id>
</element-citation>
</ref>
<ref id="r27">
<label>27.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Makiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Harita</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation</article-title>
<source/>Hum Mol Genet
          <year>2017</year>
<volume>26</volume>
<fpage>1670</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddx073</pub-id>
<pub-id pub-id-type="pmid">28335032</pub-id>
</element-citation>
</ref>
<ref id="r28">
<label>28.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Battrawy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cyganek</surname>
<given-names>L</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling short QT syndrome using human-induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>J Am Heart Assoc
          <year>2018</year>
<volume>7</volume>
<fpage>e007394</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.117.007394</pub-id>
<pub-id pub-id-type="pmid">29574456</pub-id>
</element-citation>
</ref>
<ref id="r29">
<label>29.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerrone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype</article-title>
<source/>Circulation
          <year>2014</year>
<volume>129</volume>
<fpage>1092</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.003077</pub-id>
<pub-id pub-id-type="pmid">24352520</pub-id>
</element-citation>
</ref>
<ref id="r30">
<label>30.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sallam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome</article-title>
<source/>J A
          <source/>m Coll Cardiol
          <year>2016</year>
<volume>68</volume>
<fpage>2086</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2016.07.779</pub-id>
<pub-id pub-id-type="pmid">27810048</pub-id>
</element-citation>
</ref>
<ref id="r31">
<label>31.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sendfeld</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Martinez-Moreno</surname>
<given-names>R</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient</article-title>
<source/>J Mol Cell Cardiol
          <year>2018</year>
<volume>114</volume>
<fpage>10</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.10.002</pub-id>
<pub-id pub-id-type="pmid">29024690</pub-id>
</element-citation>
</ref>
<ref id="r32">
<label>32.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>K</given-names>
</name>
</person-group>
<etal></etal>
<source/>In vitro
          <article-title>modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells</article-title>
<source/>Cell Physiol Biochem
          <year>2011</year>
<volume>28</volume>
<fpage>579</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1159/000335753</pub-id>
<pub-id pub-id-type="pmid">22178870</pub-id>
</element-citation>
</ref>
<ref id="r33">
<label>33.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells</article-title>
<source/>J Am Coll Cardiol
          <year>2012</year>
<volume>60</volume>
<fpage>990</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2012.02.066</pub-id>
<pub-id pub-id-type="pmid">22749309</pub-id>
</element-citation>
</ref>
<ref id="r34">
<label>34.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mederos y Schnitzler</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>EMBO Mol Med
          <year>2012</year>
<volume>4</volume>
<fpage>180</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1002/emmm.201100194</pub-id>
<pub-id pub-id-type="pmid">22174035</pub-id>
</element-citation>
</ref>
<ref id="r35">
<label>35.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kujala</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Paavola</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lahti</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e44660</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0044660</pub-id>
<pub-id pub-id-type="pmid">22962621</pub-id>
</element-citation>
</ref>
<ref id="r36">
<label>36.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Arbel</surname>
<given-names>G</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific drug screening using a human induced pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia type 2</article-title>
<source/>Circ Arrhythm Electrophysiol
          <year>2017</year>
<volume>10</volume>
<fpage>pii</fpage>
<lpage>e004725</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCEP.116.004725</pub-id>
<pub-id pub-id-type="pmid">28630169</pub-id>
</element-citation>
</ref>
<ref id="r37">
<label>37.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barad</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lorber</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations</article-title>
<source/>J Cell Mol Med
          <year>2015</year>
<volume>19</volume>
<fpage>2006</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1111/jcmm.12581</pub-id>
<pub-id pub-id-type="pmid">26153920</pub-id>
</element-citation>
</ref>
<ref id="r38">
<label>38.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barad</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zeevi-Levin</surname>
<given-names>N</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation</article-title>
<source/>J Cell Mol Med
          <year>2012</year>
<volume>16</volume>
<fpage>468</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2011.01476.x</pub-id>
<pub-id pub-id-type="pmid">22050625</pub-id>
</element-citation>
</ref>
<ref id="r39">
<label>39.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preininger</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>JT</given-names>
</name>
</person-group>
<etal></etal>
<article-title>A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses</article-title>
<source/>Dis Model Mech
          <year>2016</year>
<volume>9</volume>
<fpage>927</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.026823</pub-id>
<pub-id pub-id-type="pmid">27491078</pub-id>
</element-citation>
</ref>
<ref id="r40">
<label>40.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Makiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<fpage>e0164795</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0164795</pub-id>
<pub-id pub-id-type="pmid">27764147</pub-id>
</element-citation>
</ref>
<ref id="r41">
<label>41.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maron</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Towbin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Thiene</surname>
<given-names>G</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Contemporary definitions and classification of the cardiomyopathies</article-title>
<source/>Circulation
          <year>2006</year>
<volume>113</volume>
<fpage>1807</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.174287</pub-id>
<pub-id pub-id-type="pmid">16567565</pub-id>
</element-citation>
</ref>
<ref id="r42">
<label>42.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baig</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Caforio</surname>
<given-names>ALP</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease</article-title>
<source/>J Am Coll Cardiol
          <year>1998</year>
<volume>31</volume>
<fpage>195</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/S0735-1097(97)00433-6</pub-id>
<pub-id pub-id-type="pmid">9426040</pub-id>
</element-citation>
</ref>
<ref id="r43">
<label>43.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burkett</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Hershberger</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Clinical and genetic issues in familial dilated cardiomyopathy</article-title>
<source/>J Am Coll Cardiol
          <year>2005</year>
<volume>45</volume>
<fpage>969</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2004.11.066</pub-id>
<pub-id pub-id-type="pmid">15808750</pub-id>
</element-citation>
</ref>
<ref id="r44">
<label>44.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grunig</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tasman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kucherer</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Frequency and phenotypes of familial dilated cardiomyopathy</article-title>
<source/>J Am Coll Cardiol
          <year>1998</year>
<volume>31</volume>
<fpage>186</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/S0735-1097(97)00434-8</pub-id>
<pub-id pub-id-type="pmid">9426039</pub-id>
</element-citation>
</ref>
<ref id="r45">
<label>45.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Genetic causes of human heart failure</article-title>
<source/>J Clin Invest
          <year>2005</year>
<volume>115</volume>
<fpage>518</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1172/JCI24351</pub-id>
<pub-id pub-id-type="pmid">15765133</pub-id>
</element-citation>
</ref>
<ref id="r46">
<label>46.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mestroni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rocco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gregori</surname>
<given-names>D</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group</article-title>
<source/>J Am Coll Cardiol
          <year>1999</year>
<volume>34</volume>
<fpage>181</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/S0735-1097(99)00172-2</pub-id>
<pub-id pub-id-type="pmid">10400009</pub-id>
</element-citation>
</ref>
<ref id="r47">
<label>47.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dellefave</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McNally</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>The genetics of dilated cardiomyopathy</article-title>
<source/>Curr Opin Cardiol
          <year>2010</year>
<volume>25</volume>
<fpage>198</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1097/HCO.0b013e328337ba52</pub-id>
<pub-id pub-id-type="pmid">20186049</pub-id>
</element-citation>
</ref>
<ref id="r48">
<label>48.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>JW</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy</article-title>
<source/>Sci Transl Med
          <year>2012</year>
<volume>4</volume>
<fpage>130ra47</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3003552</pub-id>
<pub-id pub-id-type="pmid">22517884</pub-id>
</element-citation>
</ref>
<ref id="r49">
<label>49.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tse</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>SW</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<volume>22</volume>
<fpage>1395</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds556</pub-id>
<pub-id pub-id-type="pmid">23300193</pub-id>
</element-citation>
</ref>
<ref id="r50">
<label>50.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvajal-Vergara</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sevilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>SL</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome</article-title>
<source/>Nature
          <year>2010</year>
<volume>465</volume>
<fpage>808</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1038/nature09005</pub-id>
<pub-id pub-id-type="pmid">20535210</pub-id>
</element-citation>
</ref>
<ref id="r51">
<label>51.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Hwu</surname>
<given-names>WL</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification</article-title>
<source/>Hum Mol Genet
          <year>2011</year>
<volume>20</volume>
<fpage>4851</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr424</pub-id>
<pub-id pub-id-type="pmid">21926084</pub-id>
</element-citation>
</ref>
<ref id="r52">
<label>52.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>P</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells</article-title>
<source/>Cell Stem Cell
          <year>2013</year>
<volume>12</volume>
<fpage>101</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2012.10.010</pub-id>
<pub-id pub-id-type="pmid">23290139</pub-id>
</element-citation>
</ref>
<ref id="r53">
<label>53.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>ZJ</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling treatment response for lamin A/C related dilated cardiomyopathy in human induced pluripotent stem cells</article-title>
<source/>J Am Heart Assoc
          <year>2017</year>
<volume>6</volume>
<fpage>pii</fpage>
<lpage>e005677</lpage>
<pub-id pub-id-type="doi">10.1161/JAHA.117.005677</pub-id>
<pub-id pub-id-type="pmid">28754655</pub-id>
</element-citation>
</ref>
<ref id="r54">
<label>54.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siu</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>JC</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells</article-title>
<source/>Aging (Albany NY)
          <year>2012</year>
<volume>4</volume>
<fpage>803</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.18632/aging.100503</pub-id>
<pub-id pub-id-type="pmid">23362510</pub-id>
</element-citation>
</ref>
<ref id="r55">
<label>55.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caspi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gepstein</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells</article-title>
<source/>Circ Cardiovasc Genet
          <year>2013</year>
<volume>6</volume>
<fpage>557</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCGENETICS.113.000188</pub-id>
<pub-id pub-id-type="pmid">24200905</pub-id>
</element-citation>
</ref>
<ref id="r56">
<label>56.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>JY</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs</article-title>
<source/>Nature
          <year>2013</year>
<volume>494</volume>
<fpage>105</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1038/nature11799</pub-id>
<pub-id pub-id-type="pmid">23354045</pub-id>
</element-citation>
</ref>
<ref id="r57">
<label>57.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy</article-title>
<source/>Eur Heart J
          <year>2013</year>
<volume>34</volume>
<fpage>1122</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehs226</pub-id>
<pub-id pub-id-type="pmid">22798562</pub-id>
</element-citation>
</ref>
<ref id="r58">
<label>58.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordeiro</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Nesterenko</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Sicouri</surname>
<given-names>S</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Identification and characterization of a transient outward K<sup>+</sup> current in human induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>J Mol Cell Cardiol
          <year>2013</year>
<volume>60</volume>
<fpage>36</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.03.014</pub-id>
<pub-id pub-id-type="pmid">23542310</pub-id>
</element-citation>
</ref>
<ref id="r59">
<label>59.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dressen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geyer</surname>
<given-names>PE</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Region and cell-type resolved quantitative proteomic map of the human heart</article-title>
<source/>Nat Commun
          <year>2017</year>
<volume>8</volume>
<fpage>1469</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-017-01747-2</pub-id>
<pub-id pub-id-type="pmid">29133944</pub-id>
</element-citation>
</ref>
<ref id="r60">
<label>60.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karakikes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ameen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Termglinchan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes</article-title>
<source/>Circ Res
          <year>2015</year>
<volume>117</volume>
<fpage>80</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.305365</pub-id>
<pub-id pub-id-type="pmid">26089365</pub-id>
</element-citation>
</ref>
<ref id="r61">
<label>61.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pabon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Murry</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Circ Res
          <year>2014</year>
<volume>114</volume>
<fpage>511</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.300558</pub-id>
<pub-id pub-id-type="pmid">24481842</pub-id>
</element-citation>
</ref>
<ref id="r62">
<label>62.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ahearn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease</article-title>
<source/>Mol Ther
          <year>2006</year>
<volume>14</volume>
<fpage>831</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2006.08.009</pub-id>
<pub-id pub-id-type="pmid">17008131</pub-id>
</element-citation>
</ref>
<ref id="r63">
<label>63.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raben</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ralston</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>YH</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy</article-title>
<source/>Mol Genet Metab
          <year>2010</year>
<volume>101</volume>
<fpage>324</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2010.08.001</pub-id>
<pub-id pub-id-type="pmid">20801068</pub-id>
</element-citation>
</ref>
<ref id="r64">
<label>64.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veerman</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Kosmidis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem?</article-title>
<source/>Stem Cells Dev
          <year>2015</year>
<volume>24</volume>
<fpage>1035</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2014.0533</pub-id>
<pub-id pub-id-type="pmid">25583389</pub-id>
</element-citation>
</ref>
<ref id="r65">
<label>65.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denning</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Borgdorff</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Crutchley</surname>
<given-names>J</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform</article-title>
<source/>Biochim Biophys Acta
          <year>2016</year>
<volume>1863</volume>
<fpage>1728</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.10.014</pub-id>
<pub-id pub-id-type="pmid">26524115</pub-id>
</element-citation>
</ref>
<ref id="r66">
<label>66.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Loskill</surname>
<given-names>P</given-names>
</name>
</person-group>
<etal></etal>
<source/>In vitro
          <article-title>cardiac tissue models: Current status and future prospects</article-title>
<source/>Adv Drug Deliv Rev
          <year>2016</year>
<volume>96</volume>
<fpage>203</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.addr.2015.09.011</pub-id>
<pub-id pub-id-type="pmid">26428618</pub-id>
</element-citation>
</ref>
<ref id="r67">
<label>67.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Tampakakis</surname>
<given-names>E</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Neonatal transplantation confers maturation of PSC-derived cardiomyocytes conducive to modeling cardiomyopathy</article-title>
<source/>Cell Rep
          <year>2017</year>
<volume>18</volume>
<fpage>571</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.040</pub-id>
<pub-id pub-id-type="pmid">28076798</pub-id>
</element-citation>
</ref>
<ref id="r68">
<label>68.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunes</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Miklas</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Nat Methods
          <year>2013</year>
<volume>10</volume>
<fpage>781</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2524</pub-id>
<pub-id pub-id-type="pmid">23793239</pub-id>
</element-citation>
</ref>
<ref id="r69">
<label>69.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rana</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Christoffels</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Moorman</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>A molecular and genetic outline of cardiac morphogenesis</article-title>
<source/>Acta Physiol (Oxf)
          <year>2013</year>
<volume>207</volume>
<fpage>588</fpage>
<lpage>615</lpage>
<pub-id pub-id-type="doi">10.1111/apha.12061</pub-id>
<pub-id pub-id-type="pmid">23297764</pub-id>
</element-citation>
</ref>
<ref id="r70">
<label>70.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Making or breaking the heart: from lineage determination to morphogenesis</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>1037</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.09.003</pub-id>
<pub-id pub-id-type="pmid">16990131</pub-id>
</element-citation>
</ref>
<ref id="r71">
<label>71.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fiene</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<etal></etal>
<article-title>High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2011</year>
<volume>301</volume>
<fpage>H2006</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00694.2011</pub-id>
<pub-id pub-id-type="pmid">21890694</pub-id>
</element-citation>
</ref>
<ref id="r72">
<label>72.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gromo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company</article-title>
<source/>Cold Spring Harb Perspect Med
          <year>2014</year>
<volume>4</volume>
<fpage>a014092</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a014092</pub-id>
<pub-id pub-id-type="pmid">24890831</pub-id>
</element-citation>
</ref>
<ref id="r73">
<label>73.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritter</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP)</article-title>
<source/>Br J Clin Pharmacol
          <year>2012</year>
<volume>73</volume>
<fpage>331</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04193.x</pub-id>
<pub-id pub-id-type="pmid">22329611</pub-id>
</element-citation>
</ref>
<ref id="r74">
<label>74.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RP</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome</article-title>
<source/>EMBO J
          <year>2013</year>
<volume>32</volume>
<fpage>3161</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2013.240</pub-id>
<pub-id pub-id-type="pmid">24213244</pub-id>
</element-citation>
</ref>
<ref id="r75">
<label>75.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doss</surname>
<given-names>MX</given-names>
</name>
<name>
<surname>Di Diego</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goodrow</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr)</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e40288</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0040288</pub-id>
<pub-id pub-id-type="pmid">22815737</pub-id>
</element-citation>
</ref>
<ref id="r76">
<label>76.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kryshtal</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Feaster</surname>
<given-names>TK</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories</article-title>
<source/>J Mol Cell Cardiol
          <year>2015</year>
<volume>85</volume>
<fpage>79</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.05.003</pub-id>
<pub-id pub-id-type="pmid">25982839</pub-id>
</element-citation>
</ref>
<ref id="r77">
<label>77.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Virag</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Opinicariu</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Delayed rectifier potassium current in undiseased human ventricular myocytes</article-title>
<source/>Cardiovasc Res
          <year>1998</year>
<volume>40</volume>
<fpage>508</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/S0008-6363(98)00204-1</pub-id>
<pub-id pub-id-type="pmid">10070491</pub-id>
</element-citation>
</ref>
<ref id="r78">
<label>78.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivashchenko</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Pipes</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Lozinskaya</surname>
<given-names>IM</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2013</year>
<volume>305</volume>
<fpage>H913</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00819.2012</pub-id>
<pub-id pub-id-type="pmid">23832699</pub-id>
</element-citation>
</ref>
<ref id="r79">
<label>79.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Acsai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>B</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Contribution of I Kr and I K1 to ventricular repolarization in canine and human myocytes: is there any influence of action potential duration?</article-title>
<source/>Basic Res Cardiol
          <year>2009</year>
<volume>104</volume>
<fpage>33</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1007/s00395-008-0730-3</pub-id>
<pub-id pub-id-type="pmid">18604626</pub-id>
</element-citation>
</ref>
<ref id="r80">
<label>80.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>SW</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Toxicol Appl Pharmacol
          <year>2016</year>
<volume>296</volume>
<fpage>42</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.taap.2016.01.015</pub-id>
<pub-id pub-id-type="pmid">26821276</pub-id>
</element-citation>
</ref>
<ref id="r81">
<label>81.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Soerens</surname>
<given-names>AG</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Functional cardiomyocytes derived from human induced pluripotent stem cells</article-title>
<source/>Circ Res
          <year>2009</year>
<volume>104</volume>
<fpage>e30</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.192237</pub-id>
<pub-id pub-id-type="pmid">19213953</pub-id>
</element-citation>
</ref>
<ref id="r82">
<label>82.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D’Aniello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2014</year>
<volume>111</volume>
<fpage>e5383</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1419553111</pub-id>
<pub-id pub-id-type="pmid">25453094</pub-id>
</element-citation>
</ref>
<ref id="r83">
<label>83.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Haviland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Ca<sup>2+</sup> signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects</article-title>
<source/>Cell Calcium
          <year>2013</year>
<volume>54</volume>
<fpage>57</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceca.2013.04.004</pub-id>
<pub-id pub-id-type="pmid">23684427</pub-id>
</element-citation>
</ref>
<ref id="r84">
<label>84.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rajamohan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ronksley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Denning</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening</article-title>
<source/>Biochem Soc Trans
          <year>2010</year>
<volume>38</volume>
<fpage>1037</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1042/BST0381037</pub-id>
<pub-id pub-id-type="pmid">20659000</pub-id>
</element-citation>
</ref>
<ref id="r85">
<label>85.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Calcium handling in human induced pluripotent stem cell derived cardiomyocytes</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e18037</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0018037</pub-id>
<pub-id pub-id-type="pmid">21483779</pub-id>
</element-citation>
</ref>
<ref id="r86">
<label>86.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia</article-title>
<source/>Stem Cell Rep
          <year>2014</year>
<volume>3</volume>
<fpage>269</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2014.06.003</pub-id>
<pub-id pub-id-type="pmid">25254341</pub-id>
</element-citation>
</ref>
<ref id="r87">
<label>87.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devalla</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Gelinas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aburawi</surname>
<given-names>EH</given-names>
</name>
</person-group>
<etal></etal>
<article-title>TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT</article-title>
<source/>EMBO Mol Med
          <year>2016</year>
<volume>8</volume>
<fpage>1390</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201505719</pub-id>
<pub-id pub-id-type="pmid">27861123</pub-id>
</element-citation>
</ref>
<ref id="r88">
<label>88.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jinek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chylinski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fonfara</surname>
<given-names>I</given-names>
</name>
</person-group>
<etal></etal>
<article-title>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</article-title>
<source/>Science
          <year>2012</year>
<volume>337</volume>
<fpage>816</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1126/science.1225829</pub-id>
<pub-id pub-id-type="pmid">22745249</pub-id>
</element-citation>
</ref>
<ref id="r89">
<label>89.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hockemeyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Induced pluripotent stem cells meet genome editing</article-title>
<source/>Cell Stem Cell
          <year>2016</year>
<volume>18</volume>
<fpage>573</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2016.04.013</pub-id>
<pub-id pub-id-type="pmid">27152442</pub-id>
</element-citation>
</ref>
<ref id="r90">
<label>90.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>LS</given-names>
</name>
</person-group>
<article-title>Applications of CRISPR genome engineering in cell biology</article-title>
<source/>Trends Cell Biol
          <year>2016</year>
<volume>26</volume>
<fpage>875</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2016.08.004</pub-id>
<pub-id pub-id-type="pmid">27599850</pub-id>
</element-citation>
</ref>
<ref id="r91">
<label>91.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soldner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Stem cells, genome editing, and the path to translational medicine</article-title>
<source/>Cell
          <year>2018</year>
<volume>175</volume>
<fpage>615</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.09.010</pub-id>
<pub-id pub-id-type="pmid">30340033</pub-id>
</element-citation>
</ref>
<ref id="r92">
<label>92.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Technical challenges in using human induced pluripotent stem cells to model disease</article-title>
<source/>Cell Stem Cell
          <year>2009</year>
<volume>5</volume>
<fpage>584</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2009.11.009</pub-id>
<pub-id pub-id-type="pmid">19951687</pub-id>
</element-citation>
</ref>
<ref id="r93">
<label>93.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Almeida</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Ransohoff</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Nahid</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Immunogenicity of pluripotent stem cells and their derivatives</article-title>
<source/>Circ Res
          <year>2013</year>
<volume>112</volume>
<fpage>549</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.249243</pub-id>
<pub-id pub-id-type="pmid">23371903</pub-id>
</element-citation>
</ref>
<ref id="r94">
<label>94.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>K</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Steps toward safe cell therapy using induced pluripotent stem cells</article-title>
<source/>Circ Res
          <year>2013</year>
<volume>112</volume>
<fpage>523</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.256149</pub-id>
<pub-id pub-id-type="pmid">23371901</pub-id>
</element-citation>
</ref>
<ref id="r95">
<label>95.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YV</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Linking the p53 tumour suppressor pathway to somatic cell reprogramming</article-title>
<source/>Nature
          <year>2009</year>
<volume>460</volume>
<fpage>1140</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1038/nature08311</pub-id>
<pub-id pub-id-type="pmid">19668186</pub-id>
</element-citation>
</ref>
<ref id="r96">
<label>96.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>HL</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Somatic coding mutations in human induced pluripotent stem cells</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>63</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/nature09805</pub-id>
<pub-id pub-id-type="pmid">21368825</pub-id>
</element-citation>
</ref>
<ref id="r97">
<label>97.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masumoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration</article-title>
<source/>Sci Rep
          <year>2014</year>
<volume>4</volume>
<fpage>6716</fpage>
<pub-id pub-id-type="doi">10.1038/srep06716</pub-id>
<pub-id pub-id-type="pmid">25336194</pub-id>
</element-citation>
</ref>
<ref id="r98">
<label>98.</label>
<element-citation publication-type="journal" publisher-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Quaife-Ryan</surname>
<given-names>GA</given-names>
</name>
</person-group>
<etal></etal>
<article-title>Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway</article-title>
<source/>Cell Stem Cell
          <year>2019</year>
<volume>24</volume>
<fpage>895</fpage>
<lpage>907e6</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2019.03.009</pub-id>
<pub-id pub-id-type="pmid">30930147</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>